Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Intra-Cellular Therapies Q2 2024 GAAP EPS $(0.16) Beats $(0.20) Estimate, Sales $161.400M Beat $157.880M Estimate

Author: Benzinga Newsdesk | August 07, 2024 07:31am
Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. The company reported quarterly sales of $161.400 million which beat the analyst consensus estimate of $157.880 million by 2.23 percent. This is a 45.68 percent increase over sales of $110.792 million the same period last year.

Posted In: ITCI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist